Ligand Pharmaceuticals, Inc’s recent filing unveils that its Chief Financial Officer Espinoza Octavio unloaded Company’s shares for reported $0.24 million on Dec 23 ’24. In the deal valued at $116.37 per share,2,104 shares were sold. As a result of this transaction, Espinoza Octavio now holds 20,647 shares worth roughly $ 2.48 million.
Then, Espinoza Octavio bought 2,104 shares, generating $244,851 in total proceeds.
Before that, LAMATTINA JOHN L sold 2,406 shares. Ligand Pharmaceuticals, Inc shares valued at $297,502 were divested by the Director at a price of $123.65 per share. As a result of the transaction, LAMATTINA JOHN L now holds 29,515 shares, worth roughly $3.54 million.
Oppenheimer initiated its Ligand Pharmaceuticals, Inc [LGND] rating to an Outperform in a research note published on October 03, 2024; the price target was $135. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. H.C. Wainwright maintained its rating on February 04, 2021. It rated LGND as “a Buy”.
Price Performance Review of LGND
On Friday, Ligand Pharmaceuticals, Inc [NASDAQ:LGND] saw its stock jump 5.33% to $120.00. Over the last five days, the stock has gained 4.18%. Ligand Pharmaceuticals, Inc shares have risen nearly 11.99% since the year began. Nevertheless, the stocks have risen 69.01% over the past one year. While a 52-week high of $129.90 was reached on 01/30/25, a 52-week low of $67.72 was recorded on 01/13/25. SMA at 50 days reached $114.67, while 200 days put it at $102.57.
Levels Of Support And Resistance For LGND Stock
The 24-hour chart illustrates a support level at 115.30, which if violated will result in even more drops to 110.60. On the upside, there is a resistance level at 122.98. A further resistance level may holdings at 125.96. The Relative Strength Index (RSI) on the 14-day chart is 59.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 19.63%. Stochastics %K at 39.32% indicates the stock is a holding.
How much short interest is there in Ligand Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Ligand Pharmaceuticals, Inc stocks on 2025-01-31, growing by 51395.0 shares to a total of 0.95 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 0.9 million shares. There was a rise of 5.4%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 06, 2020 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $156 price target.
